Skip to content
SYNTHREXBiotech
KLOW Blend 80mg research vial — for laboratory research use only
KPV 10mg research vial — for laboratory research use only

Bundle

KLOW + KPV Set

KLOW Blend 80mg + KPV 10mg. A four-compound blend paired with an alpha-MSH fragment for multi-pathway research.

Test methods
HPLC-UV + LC-MS
Purity target
99%+ verified
Sizes available
1
Availability
In stock

Select size

Quantity

1

Total

$141.00

That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.

COA pending. The certificate for this lot will be uploaded to our COA library as soon as we have it.

Have a question?

For research use only. Not for human consumption.

Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.

Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.

✦ Contents

What is in this set

Every vial carries its own batch number, exactly as it would if bought separately. Every certificate is published and available for review. No published literature characterises this combination as a single entity.

KLOW Blend 80mg

A combined GHK-Cu, KPV, BPC-157 and TB-500 preparation used in multi-pathway research models.

Certificate of Analysis: LU-KL80-0626-A

Full research notes and sources for KLOW Blend →

KPV 10mg

An alpha-MSH tripeptide fragment investigated in inflammatory-pathway research.

Certificate of Analysis: J_0726-01-KPV10

Full research notes and sources for KPV →
✦ Research Notes

Research on the components

GHK-Cu

GHK is a naturally occurring tripeptide — glycyl-L-histidyl-L-lysine — identified in human plasma by Loren Pickart in 1973. Pickart was studying why plasma from young donors behaved differently from plasma from older donors in liver-cell cultures, and isolated GHK as the active factor. The copper complex GHK-Cu followed once it became clear that the tripeptide binds Cu(II) with high affinity at physiological pH, and that the copper is integral to its behaviour rather than incidental. It is one of the few compounds in this catalog with a genuinely long and independently replicated literature.

Characterised as a copper(II)-binding tripeptide. The copper coordination is the mechanistic centre: GHK-Cu acts as a copper carrier, and much of the described activity in fibroblast and dermal cell-culture models concerns copper-dependent enzyme systems and extracellular-matrix gene expression. Recent work has examined the complex in a rodent silicosis model targeting peroxiredoxin 6, and studied GHK-hyaluronan conjugates for antioxidant and osteogenic/angiogenic properties in vitro. Preclinical and in-vitro throughout. Not FDA-approved as a drug; the tripeptide appears in cosmetic formulations under separate regulatory rules.

  1. 1.Redox Biol, 2024. PMID 38879894 — peroxiredoxin 6 targeting in a rodent pulmonary model (title not reproduced here)
  2. 2.“Copper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects.” Bioconjug Chem, 2025. PMID 40123442

KPV

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone — residues 11 to 13, lysine-proline-valine. Its interest to researchers comes from a specific structural observation: the tripeptide retains a portion of α-MSH’s activity in inflammation models while lacking the melanocortin-receptor pigmentation activity of the full 13-residue hormone. That dissociation — keeping one property while dropping another — is why the fragment was pursued rather than the parent.

Characterised in murine and keratinocyte models as a melanocortin-derived tripeptide with described activity on NF-κB signalling. Published work has examined KPV in murine models of inflammatory bowel disease and studied α-MSH, MSH(11–13) KPV and ACTH signalling in human keratinocyte cells in vitro. There is also literature on transport of the tripeptide by PepT1. Animal and cell-culture work throughout. Not FDA-approved for any use.

  1. 1.Inflamm Bowel Dis, 2008. PMID 18092346 — NF-κB signalling in murine gastrointestinal models (title not reproduced here)
  2. 2.“alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.” J Invest Dermatol, 2004. PMID 15102092

BPC-157

BPC-157 traces back to a question asked at the University of Zagreb in 1975: if the stomach lining survives its own acid, does gastric juice contain something protective? Predrag Sikirić assembled a team in 1981 that collected human gastric juice from hospital gastroenterology clinics and screened the fractions for protective activity. In 1989 the group reported isolating the active fragment, and the synthetic pentadecapeptide was formally described in 1993. It is a 15-amino-acid sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.55 Da — derived from a larger protein found in gastric juice. Unusually for a peptide, it is stable in human gastric juice, which is why the original work was possible at all.

The published literature characterises BPC-157 in animal and in-vitro models as a cytoprotective agent, with reported activity on angiogenic signalling (VEGFR2 pathway), nitric oxide system interaction, and growth-factor expression in gastrointestinal and connective tissue models. The great majority of this work is preclinical — rodent and cell-culture studies. It has not been approved by the FDA for any human use, and human clinical data remains extremely limited.

  1. 1.Current Pharmaceutical Design, 2018. PMID 29879879 — vascular recruitment and cytoprotective signalling in the gastrointestinal tract (title not reproduced here)
  2. 2.Int. J. Molecular Sciences, 2026. PMID 41898733 — a review of the tissue-repair literature (title not reproduced here)

TB-500

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid peptide originally isolated from bovine thymus tissue. Its complete amino acid sequence was published in the Proceedings of the National Academy of Sciences in 1981, following work through the 1960s and 70s on biologically active thymus extracts — at that point it was understood as a thymic hormone and studied for its effect on thymocyte populations. The reframing came later, when Tβ4 was identified as a major G-actin sequestering protein. That reclassification, from immune factor to regulator of the cytoskeleton, is the reason the compound appears in tissue-repair literature at all.

Thymosin beta-4 is characterised as a principal G-actin sequestering peptide in mammalian cells: it binds monomeric (G-)actin and influences the balance between free monomer and polymerised filament, which governs cytoskeletal remodelling and cell migration. Later work has examined it as a target of hypoxia-inducible nitric oxide and HIF-1α regulation in cell-culture models. All of this is preclinical and in vitro. TB-500 is not FDA-approved for human use, and thymosin beta-4 is on the WADA Prohibited List.

  1. 1.“Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.” PNAS, 1981. PMID 6940133
  2. 2.“The actin-sequestering protein thymosin beta-4 is a novel target of hypoxia-inducible nitric oxide and HIF-1α regulation.” PLoS ONE, 2014. PMID 25271630
  3. 3.“Thymosin Beta-4, Actin-Sequestering Protein Regulates Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Nitric Oxide.” Biomolecules & Therapeutics, 2015. PMID 25593639
  4. 4.WADA Prohibited List — World Anti-Doping Agency

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Summaries of published literature for research reference only. Not a claim about any product’s effect.

Batch releases & restocks

Know when the next batch is tested

Every certificate is published and available for review. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.

Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.

Related compounds

GLOW Blend 70mg research vial — for laboratory research use only
GHK-Cu 50mg research vial — for laboratory research use only
Bundle

GLOW + GHK-Cu Set

GLOW Blend 70mg + GHK-Cu 50mg. Copper-peptide focused preparation set for dermal research models.

$127.00View
CJC-1295 + Ipamorelin Blend 10mg research vial — for laboratory research use only
Tesamorelin 5mg research vial — for laboratory research use only
Bundle

CJC-1295/Ipamorelin + Tesamorelin Set

CJC-1295 + Ipamorelin Blend 10mg + Tesamorelin 5mg. A GHRH analog / ghrelin-receptor agonist blend paired with a growth-hormone-releasing factor analog.

$131.00View

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.